Literature DB >> 26380650

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Mohamed Bouattour1, Audrey Payancé1, Johanna Wassermann1.   

Abstract

Many years after therapeutic wilderness, sorafenib finally showed a clinical benefit in patients with advanced hepatocellular carcinoma. After the primary general enthusiasm worldwide, some disappointments emerged particularly since no new treatment could exceed or at least match sorafenib in this setting. Without these new drugs, research focused on optimizing care of patients treated with sorafenib. One challenging research approach deals with identifying prognostic and predictive biomarkers of sorafenib in this population. The task still seems difficult; however appropriate investigations could resolve this dilemma, as observed for some malignancies where other drugs were used.

Entities:  

Keywords:  Antiangiogenic therapies; Functional imaging; Hepatocellular carcinoma; Predictive biomarkers; Prognosis biomarkers; Sorafenib

Year:  2015        PMID： 26380650      PMCID： PMC4568486          DOI： 10.4254/wjh.v7.i20.2245

Source DB:  PubMed          Journal:  World J Hepatol


  160 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

3.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

4.  Circulating levels of VEGF family and their receptors in hepatocellular carcinoma.

Authors:  O Kemik; A Sumer; Sarbay A Kemik; S Purisa; S Tuzun
Journal:  Bratisl Lek Listy       Date:  2010       Impact factor: 1.278

5.  Stability of phosphoprotein as a biological marker of tumor signaling.

Authors:  Amanda F Baker; Tomislav Dragovich; Nathan T Ihle; Ryan Williams; Cecilia Fenoglio-Preiser; Garth Powis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.

Authors:  Valérie Boige; David Malka; Abderrahmane Bourredjem; Clarisse Dromain; Charlotte Baey; Nathalie Jacques; Jean-Pierre Pignon; Nadege Vimond; Nathalie Bouvet-Forteau; Thierry De Baere; Michel Ducreux; Françoise Farace
Journal:  Oncologist       Date:  2012-06-15

7.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

8.  Significance of circulating endothelial progenitor cells in hepatocellular carcinoma.

Authors:  Joanna W Y Ho; Roberta W C Pang; Cecilia Lau; Chris K Sun; Wan Ching Yu; Sheung Tat Fan; Ronnie T P Poon
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

Review 9.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

10.  Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.

Authors:  D H Palmer; S A Hussain; A J Smith; S Hargreaves; Y T Ma; D Hull; P J Johnson; P J Ross
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640
View more
  4 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

2.  Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study.

Authors:  Marta Campos; Isabel Candelária; Nickolas Papanikolaou; Adélia Simão; Carlos Ferreira; Georgios C Manikis; Filipe Caseiro-Alves
Journal:  GE Port J Gastroenterol       Date:  2019-02-18

3.  The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker.

Authors:  Ping Yang; Na Chen; Dongyun Yang; Janet Crane; Shouhua Yang; Hangyu Wang; Ruiqing Dong; Xiaoqing Yi; Lisha Xie; Guo Jing; Jing Cai; Zehua Wang
Journal:  PeerJ       Date:  2017-05-30       Impact factor: 2.984

4.  Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.

Authors:  Wang-De Hsiao; Cheng-Yuan Peng; Po-Heng Chuang; Hsueh-Chou Lai; Ken-Sheng Cheng; Jen-Wei Chou; Yang-Yuan Chen; Cheng-Ju Yu; Chun-Lung Feng; Wen-Pang Su; Sheng-Hung Chen; Jung-Ta Kao
Journal:  BMC Gastroenterol       Date:  2016-04-27       Impact factor: 3.067
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.